Opthea (OPT) News Today $3.41 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Opthea (NASDAQ:OPT) Stock Price Up 7.2% - Time to Buy?July 4, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Shares Gap Up - Here's WhyJuly 3, 2025 | marketbeat.comBiocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expectedJuly 2, 2025 | msn.comOpthea Limited (NASDAQ:OPT) Given Average Recommendation of "Hold" by BrokeragesJune 9, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Trading Up 7.2% - What's Next?June 6, 2025 | marketbeat.comOpthea Faces Leadership Changes Amidst Clinical Trial SetbacksJune 1, 2025 | tipranks.comOpthea Limited (NASDAQ:OPT) Given Average Rating of "Hold" by AnalystsMay 17, 2025 | marketbeat.comHsbc Holdings PLC Makes New Investment in Opthea Limited (NASDAQ:OPT)May 9, 2025 | marketbeat.comBiotech Dimerix lands $940m licensing deal for kidney drug salesMay 1, 2025 | afr.comPhil King’s Regal successfully bets against Tesla, NvidiaMay 1, 2025 | afr.comOpthea Limited (NASDAQ:OPT) Receives Average Recommendation of "Hold" from AnalystsApril 22, 2025 | marketbeat.comRegal’s King says his hedge funds will recover from March madnessApril 16, 2025 | afr.comRegal: Don’t catch the falling knife, wait for it to stick in the floorApril 16, 2025 | msn.comBELL POTTER SECURITIES Downgrades Opthea (CKDXF)April 9, 2025 | msn.comBELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)April 9, 2025 | msn.comASX drops as US jumbo China tariff takes effectApril 9, 2025 | afr.comShort Interest in Opthea Limited (NASDAQ:OPT) Expands By 20.7%April 4, 2025 | marketbeat.comOpthea Limited (CKDXF) was downgraded to a Sell Rating at Bell PotterApril 3, 2025 | markets.businessinsider.comPhil King’s Regal writes Opthea to zero and backs off risky betsApril 2, 2025 | afr.comOpthea Ends Development of Sozinibercept in Wet AMDMarch 31, 2025 | marketwatch.comOpthea terminates COAST trial, announces ShORe trial misses endpointMarch 31, 2025 | markets.businessinsider.comOpthea Announces Decision to Discontinue Wet AMD TrialsMarch 30, 2025 | globenewswire.comOpthea Limited’s Securities Suspended Due to Financial ConcernsMarch 30, 2025 | tipranks.comJPMorgan Chase Acquires Substantial Stake in Opthea LimitedMarch 30, 2025 | tipranks.comResearch Analysts Issue Forecasts for Opthea FY2025 EarningsMarch 28, 2025 | marketbeat.comFY2025 EPS Estimates for Opthea Decreased by Leerink PartnrsMarch 28, 2025 | marketbeat.comHotCopper Highlights for Week 13 – Opthea, Reject Shop, Bellevue & more!March 28, 2025 | msn.comThe clinical trial result from hell has biotech investors on edgeMarch 28, 2025 | afr.comOpthea Limited (NASDAQ:OPT) Receives Consensus Rating of "Hold" from BrokeragesMarch 27, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Downgraded by Leerink Partnrs to HoldMarch 27, 2025 | marketbeat.comPengana freezes fund redemptions as it braces for big Opthea lossMarch 27, 2025 | afr.comOpthea (NASDAQ:OPT) Downgraded to "Neutral" Rating by HC WainwrightMarch 26, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Stock Rating Lowered by Leerink PartnersMarch 26, 2025 | marketbeat.comOpthea's (OPT) Underperform Rating Reaffirmed at Jefferies Financial GroupMarch 26, 2025 | marketbeat.comOpthea cut to Market Perform at Leerink on failed sozinibercept trialMarch 25, 2025 | markets.businessinsider.comOpthea double downgraded to Underperform from Buy at JefferiesMarch 25, 2025 | markets.businessinsider.comHearts and Minds Investments Updates on Opthea Limited Portfolio ImpactMarch 25, 2025 | tipranks.comOppenheimer Downgrades Opthea (NASDAQ:OPT) to Market PerformMarch 25, 2025 | marketbeat.comHold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial FailureMarch 25, 2025 | tipranks.comOpthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial UncertaintyMarch 25, 2025 | tipranks.comOpthea COAST trial misses primary endpoint, enters talks with DFA InvestorsMarch 24, 2025 | markets.businessinsider.comAmid fears of collapse, what's happening with Opthea ASX shares today?March 24, 2025 | msn.comMonday’s HotCopper Trends: Opthea strife, Memphasys best-in-class results | March 21, 2025March 24, 2025 | msn.comOpthea's Phase 3 trial results fail to help patients, future of company at riskMarch 24, 2025 | msn.comOpthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial UncertaintyMarch 24, 2025 | benzinga.comOpthea Announces COAST Phase 3 Trial Topline ResultsMarch 23, 2025 | globenewswire.comOpthea Limited Suspends Trading Pending Clinical Trial ResultsMarch 18, 2025 | tipranks.comHealth Check: Awaiting key announcements, these biotechs could use some Irish luckMarch 16, 2025 | msn.comOpthea Limited Initiates Trading Halt Ahead of Key Clinical Trial ResultsMarch 16, 2025 | tipranks.comOpthea (NASDAQ:OPT) Shares Gap Up - Time to Buy?March 15, 2025 | marketbeat.com Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address OPT Media Mentions By Week OPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPT News Sentiment▼1.870.99▲Average Medical News Sentiment OPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPT Articles This Week▼13▲OPT Articles Average Week Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGIO News CGON News KNSA News BEAM News IDYA News IRON News BLTE News CNTA News HRMY News ADPT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPT) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPT Stock Alerts